David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.
Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.
Dr. Crean’s pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOM’s Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.
Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.